Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?

Reddy, Venkat, Dahal, Lekh N., Cragg, Mark S. and Leandro, Maria (2016) Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer? Drug Discovery Today, 21 (8), 1330-1338. (doi:10.1016/j.drudis.2016.06.009). (PMID:27343722)

Record type: Article

Abstract

In Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE), B-cell depletion therapy using rituximab results in variable clinical responses between individuals, which likely relates to variable B-cell depletion in the presence of immune defects. Outcomes in clinical trials with other type I anti-CD20 mAbs, ocrelizumab and ofatumumab, are comparable to rituximab. A mechanistically different type II mAb, obinutuzumab (OBZ), with greater capacity for B-cell depletion, has recently entered clinical trials in SLE. Here we consider whether type II anti-CD20 mAbs will provide mechanistic advantages to overcome the disease-related immune defects in autoimmune diseases such as SLE.

Text

DRUDIS-D-16-00044 submitted manuscript.pdf - Accepted Manuscript

Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (779kB)